2 | DIAGNOSIS CS occurs in 1 in 10-15,000 live births and most commonly results from de novo heterozygous, pathogenic, loss-of-function variants in the CHD7 gene on chromosome 8, resulting in haploinsufficiency (Vissers et al., 2004) . The spectrum of pathogenic CHD7 variants in CS is summarized nicely by Bergman et al. (2011) : pathogenic variants are identified in up to 90% of patients with a clinical diagnosis of CS, with truncating variants being most frequent, missense mutations present in a minority of patients, and partial or full CHD7 deletions rare (Janssen et al., 2012) .
Despite the identification of pathogenic CHD7 variants in the majority of cases, the diagnosis of CS remains clinical (Hale, Niederriter, Green, & Martin, 2016; Trider, Arra-Robar, van Ravenswaaij-Arts, & Blake, 2017) with genetic testing being particularly helpful in borderline clinical cases. The clinical diagnostic criteria have undergone a number of revisions since the original description by Pagon, Zonana, and Yong (1981) without a clear consensus (Blake et al., 1998; Verloes, 2005; Hale et al., 2016) . All three schemes require a minimum of two major diagnostic features with several supporting features for a clinical diagnosis, but which features should be considered as major and which supporting vary between criteria, as illustrated in Table 1 . Blake et al. (1998) emphasize the importance of cranial nerve abnormalities as major features and described criteria for "definite" CS. Verloes (2005) added semicircular canal abnormalities as a major feature and described "typical" and "atypical" CS. Hale et al. (2016) added CHD7 pathogenic variants as a major feature and described broader "inclusion" criteria. Continued discussion and additional information from molecular genetic testing and animal models may help clarify the clinical diagnostic criteria for CS.
Evaluations which are most helpful for both diagnosis and medical management of CS are described in detail elsewhere (Blake et al., 1998; Lalani et al., 2006; Trider et al., 2017; Verloes, 2005) .
| When to consider CHARGE syndrome?
Any number of features may trigger an initial consideration of CS. A common scenario is an infant with multiple anomalies including at least one of the more obvious birth defects or dysmorphic features most associated with CS: coloboma, choanal atresia, and/or CS external ears (Table 1 and Figure 1 ). Any patient with one or more of the major features of CS in conjunction with other anomalies should be evaluated for possible CS. In the prenatal setting, CS should be considered when congenital heart defects are identified with other anomalies and chromosomal microarray (CMA) has not provided a diagnosis.
| Differential diagnosis
As CS can affect any organ system in the body, the features overlap with countless other syndromes. The top candidates in the differential diagnosis of CS are 22q11.2 deletion syndrome (22q) and Kabuki syndrome (KS).
VACTERL association also has a good deal of overlap, but typically does not have significant dysmorphic features. Nearly every feature reported in each of the three genetic conditions (CS, 22q, and KS) has also been reported at least rarely in each of the others, but the relative frequency of many of the common features varies, as illustrated in Table 2 . When present, the dysmorphic features specific to each syndrome may be particularly helpful in distinguishing among them. 
| Genetic testing recommendations
CMA is often performed initially for fetuses or infants with multiple anomalies. This is reasonable as 22q is far more common than CS and CMA can identify other rare microdeletions or microduplications 
| Other diagnostic evaluation recommendations
The most ubiquitous feature of CS is hypoplastic semicircular canals (SCC) (Vesseur et al., 2016) which is present in more than 95% of cases FIGURE 1 Dysmorphic Features of CHARGE Syndrome: Face, Hands, Ears Legend: Line a, Face: square, flat face with prominent forehead, high nasal bridge, prominent nasal columella (a1, a3). Asymmetry due to facial palsy (a1, a2). Eyes large and round, often with epicanthal folds (a2). Note iris colobomata in a2, sloping shoulders in a3, and floppy ears in all three. No cleft lips shown. Line b, Hand: hockey-stick palmar crease (b1, b2), finger-like thumb (b1), short fingers, sometimes tapered, square palm(b3). Polydactyly and ectrodactyly have been reported. Line c, Ears: c1, c2, and c3 are right and left ears from three individuals. Short, wide ears with small or absent lobe, unfolded or "snipped off" helical folds, triangular concha, discontinuity between tragus and antitragus. Ears are floppy due to decreased cartilage and usually asymmetric. References: Davenport, Hefner, and Mitchell (1986) ; Davenport, Hefner, and Thelin (1986) ; Blake et al. (1998) , Hartshorne et al. (2011) of CS and is an unusual finding in other syndromes. As knowledge of hypoplastic SCC is also important for management of developmental issues, temporal bone imaging (CT or MRI) is recommended for all cases of possible CS. Trider et al. (2017) Blake et al. (1998) and expanded in the GeneReviews (Lalani et al., 2006) and book on CHARGE (Hartshorne, Hefner, Davenport, & Thelin, 2011 
| Developmental/educational management
The vast majority of individuals with CS will have at least some degree of hearing loss (90-95%) and some degree of vision loss (80-90%), and therefore will be considered deafblind. "Deafblind"
(DB) is an educational term which refers to individuals whose combination of hearing and vision loss limits access to auditory and visual information and creates unique challenges for communication and education (National Center on Deaf-Blindness, 2017). In addition, nearly all individuals with CS have small or absent SCC, a vital component of the vestibular system. The vestibular system is responsible not only for balance (one's internal "level") but also for processing of visual information (one's internal "Steadicam") and processing of auditory information (Brown, 2011 , Thelin, Curtis, Maddox, & Travis, 2011 defects, facial clefts, kidney problems, polyhydramnios) which prompt prenatal testing (CMA), with or without genetic counseling. With the exception of very rare microdeletions encompassing the CHD7 gene, CMA will not identify CS (although it will rule out 22q11 deletion syndrome). Women are told "the genetic testing was normal," which they often take to mean the birth defects or prenatal findings are not linked to an underlying syndrome and they should not expect any issues beyond what was identified on ultrasound.
| Genetic counseling implications
We heard Turner's, then Noonan's, then CHARGE, and each new term caused a rush of researching on our part.
If CS is being considered, the child has multiple issues and there will be other conditions on the differential diagnosis. Often long before a diagnosis is made, the child has already been evaluated by multiple specialists and the family is confused and frightened.
Explaining why multiple evaluations are needed and including the normal/negative findings may help ease some of the family's anxiety, as can having one point person to interact with the family. Here is how one family described their experience with multiple specialists:
What happens next will feel awful and inconsiderate and rude. Those doctors will start to shuffle in, one after the other, and they will each drop more bad news. to family that obtaining a diagnosis will not change anything in terms of treatment in that moment (if that is the case) and the family may decide that they would like to plan for this discussion of diagnostic testing at a later date and just make yourself available for questions in the meantime.
| Dual diagnosis?
A common confusion for parents is the idea that their child has more than one condition: "My child has CHARGE and Kallmann syndrome," "My child has CHARGE and DiGeorge." An important counseling point is that CS can include a multitude of features, and each child has her own unique set of CS features. Some of those features, if they were found in isolation in a child, might be labeled as another specific syndrome. By this point, we knew she needed open heart surgery, surgery to fix her atresia, there was talk about a g-tube placement, were told she was basically blind and deaf, and that she may not walk or communicate with us.
Parents report feeling that the diagnosis of CS was explained largely in a negative manner (i.e., focusing on the things that children with CS will struggle to do) rather than the diagnosis being framed in a more positive or neutral light. This is important for the genetic counselor to keep in mind when communicating a diagnosis.
Stressing what may be achievable is more helpful to the family than what the child may not do. For example, the vast majority of individuals who are legally blind still retain some usable vision, so talking about ways to use low vision is more helpful than stating that a child will be blind. It is vital for genetic counseling to include accurate information about the developmental prognosis in CS.
Ultimate intellectual capacity in individuals with CS runs the gamut from severely disabled to completely normal and is not correlated with severity of birth defects. Between a quarter and half of all individuals with CS appear to be in the range of normal cognitive functioning (Raqbi et al., 2003; Salem-Hartshorne & Jacob. 2005) . As adults, individuals with CS have a range of abilities and are in a variety of living situations from completely independent, to living with family, living in a group home, or requiring complete care. Due to multiple sensory deficits, the majority of adults with CS will require at least some assistance or accommodation.
As infants and children, all individuals with CS are expected to have delayed development-typically very delayed. This delay is due to three main factors-and the degree of delay is not a predictor of ultimate outcome. The first factor is the time spent in hospital, recovering from surgery, or simply being ill. This is time when development will not be progressing at anything near a normal rate and in fact may regress. Expectations for development need to be age-adjusted for time lost to treatment of and recovery from medical issues in the same way that expectations are adjusted for premature infants. The second factor is the impact of the physical characteristics of CS such as truncal hypotonia, facial palsy, cleft palate, feeding, and breathing issues. When present, these will delay development even in the presence of normal intelligence and relatively good health. The third and most significant factor is the presence of multiple sensory deficits 
| What is a genetic counselor to do?
It is not necessary for the genetic counselor (GC) to become an expert in deafblindness or multiple sensory deficits. The role of the GC here is to help the families understand that although there will be delayed development, much of the delay is due to the combination of medical/health issues and multiple sensory deficits and to connect the family to appropriate resources. "Delay" is an appropriate term: many individuals with CS do eventually catch up. There are resources and therapies specifically designed to assist in development in the presence of sensory deficits and deafblindness. Referrals to early intervention services and local or regional deafblind services should be done as early as possible and repeated at subsequent visits in case the family has not followed up.
In the US, every state has a Deafblind (DB) Project, which is tasked specifically to assist children with combined hearing and vision loss from birth through age 21 years. Similar organizations and programs exist in many other countries (Table 3) . DB projects work with early intervention, therapists, schools, and families to develop and implement appropriate programs for each child and to help with transition at various levels. The websites of the CHARGE Syndrome
Foundation and other organizations include links to resources specifically created for people who work with CS, including many throughout the world. Those and other resources are listed in Table 3 .
| Genetic counseling: Individuals with CHARGE
Adolescents and young adults with CS may desire genetic counseling themselves. Many are interested to know what to expect as they age-both in terms of health and wellbeing. Many adults with CS are interested in having families and want to know about recurrence risk, reproductive options, and fertility. Although some individuals with CS go through puberty normally and are fertile, data are currently limited regarding fertility for those requiring intervention to achieve puberty.
It is important to counsel individuals with CS that any biological children who are also affected may present differently-with milder or more severe features than the affected parent (e.g., Mitchell, Giangiacomo, Hefner, Thelin, & Pickens, 1985) . Further research in all of these areas is needed.
| Genetic counseling: Recurrence risks
Recurrence risks are summarized in Table 4 . For parents, a discussion of recurrence risk is important, but usually not always immediately after the diagnosis is made. As one parent stated:
Given this was our first child and we were flooded with information on how to care for her g-tube, trach, etc., recurrence risk was not a priority in the beginning . . . It wasn't until our daughter was closer to 2 years old that we started thinking about having another child and wanted to learn more about recurrence risk .... I think it will also be HEFNER AND FASSI | 413 important to research the matter more again when and if she gets to a point of looking to have children.
Ideally, recurrence risk would be discussed at a follow-up visit or when parents inquire about the issue. Recurrence risk information should also be provided in writing, along with any family genetic test results and information about reproductive options or whom to contact to get more information about reproductive options.
Precise genetic diagnosis is required before a family can be given accurate information about recurrence or be offered prenatal testing.
Most often, CS is caused by unique, de novo pathogenic variants in the CHD7 gene on chromosome 8. Familial cases have been reported, including parent-to-child transmission (Bergman et al., 2011) . Cases of parent-to-child transmission are more often due to pathogenic missense (rather than truncating) variants (Bergman et al., 2011; Jongmans et al., 2008) . Once the variant in the child is known, parental targeted variant analysis is recommended. As with other de novo dominant mutations, there is a recurrence risk of 1-2% for parents of a child with a de novo variant due to rare instances of gonadal mosaicism in one of the parents.
It is important to keep in mind that CS is extremely variable in its presentation and does not run true in families and through generations.
Siblings affected due to gonadal mosaicism or children of affected parents may have vastly different presentations of CS.
2.12 | Preimplantation and prenatal testing 2.12.1 | Recurrence risks
As with other genetic conditions, when the precise variant in a family is known and there is a risk of recurrence, preimplantation genetic testing or prenatal diagnosis by CVS or amniocentesis is possible and options should be presented to the parents as part of extensive genetic counseling (Table 4) . Those who have declined invasive testing may still elect serial ultrasounds to assess for structural defects associated with CS. 3D images of the ears can be particularly helpful in addition to the anatomic survey.
The Family Planning issue of the CHARGE Accounts newsletter (Table 3) includes a list of ultrasound features associated with CS.
2.12.2 | Significant ultrasound findings in families with no history of CS When a heart defect is noted along with other significant findings on prenatal ultrasound, CS should be considered in the differential diagnosis especially if CMA has been performed and is nondiagnostic (i.e., trisomies and 22q have been ruled out). CHD7 sequencing or WES should be considered in such cases. Non-invasive prenatal testing (NIPT) which analyzes single genes including CHD7 in maternal serum cell-free DNA may provide a non-invasive option in some cases. 
| Maternal serum screening
With rapid advances in prenatal screening using cell-free fetal DNA in maternal serum, de novo CHD7 variants may be suspected early in pregnancy even before ultrasound abnormalities are detected.
Genetic counseling in these cases presents a challenge as the CS phenotype is extremely variable and cannot be reliably predicted by genotype (see paper in this issue on genotype-phenotype in CS).
Pregnancies with possible CS or CHD7 variants identified via noninvasive genetic screening should be offered diagnostic genetic testing and imaging (e.g., ultrasound, MRI) as part of the evaluation and counseling process.
In summary, CS is a particularly complex syndrome, with each feature varying from severe to absent in different children. Every patient with CS has his or her own unique set of features and challenges. Navigating with the family through the maze of diagnosis, management, follow up, and referrals requires all of the skills of the genetics team. Care should be taken to provide families with accurate information, support, and resources without overwhelming them with information at one visit. CS-more than many syndromes-requires ongoing genetic counseling through many visits over many years. The process can be a very rewarding experience for the counselor, the family, and the patient. 
